Adverse Events Associated with Immune Checkpoint Inhibitors - Reply

Douglas B. Johnson, Sunandana Chandra, Jeffrey A. Sosman*

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)1219-1220
Number of pages2
JournalJAMA - Journal of the American Medical Association
Volume321
Issue number12
DOIs
StatePublished - Mar 26 2019

Funding

from the National Cancer Institute and the James C. Bradford Jr Melanoma Fund; serving on advisory boards for Array Biopharma, Bristol-Myers Squibb, Incyte, Merck, Novartis, and Genoptix; and receiving research grants from Bristol-Myers Squibb and Incyte. Dr Chandra reported receiving consulting fees from Bristol-Myers Squibb, EMD Serono, Regeneron, Novartis, and Array Biopharma. Dr Sosman reported receiving funding from the Mary Hendrickson-Johnson American Cancer Society Melanoma Research Professorship; serving on advisory boards for Array Biopharma, Bristol-Myers Squibb, and Genentech; and receiving research funding from Merck.

ASJC Scopus subject areas

  • General Medicine

Cite this